Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MAINtenance Afinitor: A Randomized Trial Comparing Maintenance Aromatase Inhibitors (AIs) + Everolimus (Afinitor) vs AIs in Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients With Disease Control After First Line Chemotherapy

NCT02511639 is registered in ClinicalTrials.gov with Istituto Oncologico Veneto IRCCS as lead sponsor.

NCT NCT02511639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02511639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MAINtenance Afinitor: A Randomized Trial Comparing Maintenance Aromatase Inhibitors (AIs) + Everolimus (Afinitor) vs AIs in Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients With Disease Control After First Line Chemotherapy
Lead sponsor
Istituto Oncologico Veneto IRCCS
Phase
Phase 3
Overall status
Completed
Start date
July 30, 2014
Completion date
July 31, 2020
Enrollment
110 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic